Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
Methods are provided for treating hematological disorders by inhibition of DNA hypomethylation and histone deacetylase. Such disorders include, for example, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia. The methods comprise: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
1. A method for treating a hematological disorder of a patient comprising:
administering to the patient suffering from the hematological disorder a therapeutically effective amount of a DNA methylation inhibitor selected from the group consisting of decitabine and 5-azacytidine at a dose ranging from 1 to 50 mg/M 2 per day, in combination with an effective amount of histone deacetylase inhibitor selected from the group consisting of trichostatin A, suberoylanilide hydroxamic acid, oxamflatin, suberic bishydroxamic acid, m-carboxy-cinnamic acid bishydroxamic acid, pyroxamide, trapoxin A, apicidin, depsipeptide, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide, butyric acid, phenylbutyrate and arginine butyrate.
2. The method of claim 1 , wherein the hematological disorders is selected from the group consisting of acute myeloid leukemia, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia.
3. The method of claim 1 , wherein administering to the patient includes administering the DNA methylation inhibitor and the histone deacetylase inhibitor orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, or intrathecally.
4. The method of claim 1 , wherein the DNA methylation inhibitor is decitabine and is administered intravenously or subcutaneously.
5. The method of claim 4 , wherein decitabine is administered to the patient via an intravenous infusion per day at a dose ranging from 2 to 50 mg/m 2 .
6. The method of claim 4 , wherein decitabine is administered to the patient via an intravenous infusion per day at a dose ranging from 5 to 20 mg/m 2 .
7. The method of claim 4 , wherein decitabine is administered to the patient via an intravenous infusion per day for at least 3 days per treatment cycle at a dose ranging from 1 to 50 mg/m 2 .
8. The method of claim 1 , wherein the histone deacetylase inhibitor is depsipeptide and administered intravenously.
9. The method of claim 8 , wherein depsipeptide is administered to a patient by continuous intravenous infusion for at least 4 hours per day for a week at a dose ranging from 2 to 100 mg/m 2 .
10. The method of claim 8 , wherein depsipeptide is administered to a patient by continuous intravenous infusion for at least 4 hours per day for a week at a dose ranging from 5 to 50 mg/m 2 .
11. The method of claim 8 , wherein depsipeptide is administered to a patient by continuous intravenous infusion for at least 4 hours per day for a week at a dose ranging from 5 to 15 mg/m 2 .
12. The method of claim 1 , wherein the histone deacetylase inhibitor is phenylbutyrate and administered intravenously.
13. The method of claim 12 , herein phenylbutyrate is administered to the patient by continuous intravenous infusion for at least 2 to 3 weeks at a dose ranging from 100-2000 mg/m 2 .
14. The method of claim 12 , wherein phenylbutyrate is administered to the patient by continuous intravenous infusion for at least 2 to 3 weeks at a dose ranging from 250-1000 mg/m 2 .
15. The method of claim 12 , wherein phenylbutyrate is administered to the patient by continuous intravenous infusion for at least 2 to 3 weeks at a dose ranging from 500-800 mg/m 2 .
16. The method of claim 1 , wherein the DNA methylation inhibitor is administered prior to the administration of the histone deacetylase inhibitor.